The ampicillin-sulbactam combination was evaluated in vitro to determine the optimal susceptibility testing conditions among five combination ratios and four fixed concentrations of sulbactam. The organisms tested were markedly resistant to aminopenicillins and most other beta-lactams. The ratio of 2:1 is recommended to assure recognition of the ampicillin-sulbactam spectrum and minimize false-susceptible results among strains known to be resistant to this combination. Proposed MIC breakpoint concentrations were compatible with levels in serum achieved with recommended clinical doses. Cross-resistance analyses comparing ampicillinsulbactam and amoxicillin-clavulànate showed comparable activity and spectra. However, the major interpretive disagreement was sufficient to require separate testing of these aminopenicillin-inhibitor combinations. The recommended ampicillin-sulbactam MIC susceptibility breakpoints are as follows: (i) <8.0/4.0 ,ug/ml for tests against members of the family Enterobacteriaceae, anaerobes, nonenteric gram-negative bacilli, staphylococci, Haemophilus influenzae, and Branhamella catarrhalis; (ii) the ampicillin MICs alone interpreted by National Committee for Clinical Laboratory Standards criteria should predict ampicillin-sulbactam susceptibility for the enterococci, streptococci, and Listeria monocytogenes. MIC quality control ranges were determined by multiple laboratory broth microdilution trials for the ampicillin-sulbactam 1:1 and 2:1 ratio tests.
The ampicillin-sulbactam combination is one of several available penicillin-beta-lactamase inhibitor drugs that have a wide spectrum of antimicrobial activity (1, 2, 3, 6, 7, 15, 16, 19, 20 ; R. N. Jones, Drugs, in press). The sulfone betalactamase inhibitor sulbactam has an excellent affinity for the clinically prevalent plasmid-mediated bacterial enzymes that can readily hydrolyze the aminopenicillins (7, 16, 17; Jones, in press). The combination of ampicillin and sulbactam is a particularly good choice since it combines the reliable antimicrobial activity of ampicillin against enterococci, streptococci, and beta-lactamase-negative strains of enteric bacilli with that of the combination, which also inhibits penicillinase-producing Staphylococcus spp. and Neisseria gonorrhoeae, beta-lactamase-positive Haemophilus influenza and Branhamella catarrhalis, Bacteroides fragilis group species, and many more members of the family Enterobacteriaceae (2, 7, 16 ; Jones, in press).
Ampicillin-sulbactam has been studied clinically as an orally administered ester combination and as a parenteral combination usually administered in equal doses of each drug or as a 2:1 ratio of ampicillin to sulbactam (11) . The pharmacokinetics of each component in humans are very similar and the drug ratios in serum or tissue vary between 1:1 and 2:1 (ampicillin-sulbactam) depending upon the doses administered (5, 8) .
In this report, we summarize the results of investigations to determine the best in vitro dilution susceptibility test conditions for the ampicillin-sulbactam combination. We also report the results of a multilaboratory study to establish broth microdilution MIC quality control (QC) guidelines. (12) (13) (14) or direct beta-lactamase detection methods, 63.8% of the strains were ampicillin resistant. These organisms differ greatly from the strains used in our earlier studies of beta-lactamase inhibitor combinations or those routinely encountered in clinical practice (3, 4, 9; Jones, in press).
MATERIALS AND METHODS
Antimicrobial susceptibility testing and beta-lactamase detection methods. The MICs were determined by the broth microdilution method described in detail previously (4, 9; Jones, in press) and by the National Committee for Clinical Laboratory Standards (NCCLS) (13) . The inoculum con- Comparison of these two inhibitor combinations against the 78 non-Enterobacteriaceae gram-negative bacilli indicated greater activity for amoxicillin-clavulanate. Three strains of P. maltophilia and two strains of P. acidovorans were susceptible only to amoxicillin-clavulanate. The absolute agreement between these drug combinations was 88.2%, with 9.8% minor and 2.0% major (false-susceptible or -resistant) discrepancies. However, since many of the major errors were among the E. coli isolates (nearly 50% of routine enteric isolates), the small major error rate may be greatly amplified in some Enterobacteriaceae populations.
Comparison of the two combination MICs for the enterococci (r = 0.93) and streptococci (r = 0.98) showed nearly identical results indistinguishable from the comparison of activity of their active aminopenicillin components. Similarly, the staphylococcal, B. catarrhalis, and H. influenzae correlation coefficients were >0.95, with 100% interpretive agreement using the previously published susceptible amoxicillin-clavulanate breakpoints for both combinations (4, 9, 12, 13; Jones, in press).
Ampicillin-sulbactam MlC QC. The results of a prospective multilaboratory investigation to determine ampicillinsulbactam QC guidelines for broth microdilution MIC tests are shown in Table 6 . The five centers reported 20 MICs for each QC strain and five additional MICs for each organism determined with a common lot of broth microdilution panels. The control drug was ampicillin, and all MICs were within the QC range recommended by the NCCLS (14) . The two tested ampicillin-sulbactam ratios each gave very similar results. The proposed QC limits for the 1:1 and 2:1 ratios are as follows: (i) for E. coli ATCC 25922, 2.0 to 8.0 ,ug/ml; (ii) for E. coli ATCC 35218, 4.0 to 16 ,xg/ml; (iii) for E. faecalis ATCC 29213, 0.5 to 2.0 p.g/ml; and (iv) for S. aureus ATCC 29213, 0.25 to 1.0 ,ug/ml. These are identical to those for ampicillin alone, except for E. coli ATCC 35218, for which the mode was >32 ,ug/ml. All QC organism MICs (36 MICs for three organisms) obtained during the ampicillin-sulbactam combination experiments described above were within these guidelines.
DISCUSSION
Several beta-lactamase inhibitors have been developed that enhance the antimicrobial activity and spectra of betalactam drugs used in combination with them (1, 2, 7, 16) . Among these inhibitors, sulbactam has received extensive in vitro and in vivo evaluations combined with ampicillin and cefoperazone (15; Jones, in press). Sulbactam restores the efficacy of ampicillin which existed before the era of more prevalent beta-lactamase production by bacterial species such as members of the Enterobacteriaceae, H. influenza, N. gonorrhoeae, staphylococci, and gram-negative anaerobes (1, 2, 3, 4, 6, 7, 15, 16, 19, 20 ; Jones, in press). Sulfone beta-lactamase inhibitors have excellent affinity for the plasmid-mediated enzymes found to be most prevalent in clinically important organisms (17) and also have marginal inhibitory activity against some type I and IV betalactamases (2, 15; Jones, in press). Thus, sulbactam becomes a potent irreversible enzyme inhibitor with excellent bactericidal activity when combined with ampicillin against a by chromosomally mediated beta-lactamases (2, 16) . Synergy was also found in the absence of beta-lactamase production, indicating an alternate mode of sulbactam interaction with beta-lactam co-drugs (2) . This finding indicates that ampicillin-sulbactam has a slightly wider spectrum of activity against some members of the Enterobacteriaceae compared with amoxicillin-clavulanic acid (Jones, in press).
ORS are also inhibited by ampicillin-sulbactam at clinically achievable drug levels (8, 15 ; Jones, in press). It is postulated that the beta-lactamase inhibitor "unmasks" the usable activity of ampicillin directly on the ORS, an activity that can be two-to eightfold greater than that of penicillinase-resistant penicillins (15) . Aminopenicillins may have greater affinity for the altered penicillin-binding proteins than does oxacillin or methicillin (10) . Ampicillin-sulbactam therapy has been successful in the rabbit endocarditis model and other animal models for infections caused by ORS (6, 15, 16, 18 (3, 19) .
Human pharmacokinetic studies with parenteral ampicillin-sulbactam assure levels of the active beta-lactam and inhibitor that allow susceptible breakpoint concentrations, including s4 ,ug of sulbactam per ml (5, 8) . The concentrations of each component in body fluids and tissues usually vary by about an average of a 1:1 to 2:1 ratio with the recommended 2:1 dosing ratio (5) . At the lowest anticipated clinical dose, 0.5 g of sulbactam, delivered by intramuscular injection, a peak of only 13 ,ug/mi was observed (8) . Similarly, Brown et al. (5) found sulbactam blister fluid peaks with a 500-mg intravenous administration to be 19.2 Fg/ml, a value comparable to concentrations in serum. Therefore, the conservative level of sulbactam for use in the in vitro susceptibility test system appears to be c4.0 Ftg of sulbactam per ml. The half-lives of these two drugs in serum are very similar, 1 to 1.5 h.
In susceptibility testing with any beta-lactamase inhibitor, it must first be considered whether the inhibitor can be delivered at a sufficient concentration in vivo to prevent beta-lactamase hydrolysis of the co-drug. This has been achieved for the ampicillin-sulbactam combination and at the clinically recommended dosage (2 g of ampicillin and 1 g of sulbactam every 6 to 8 h), favors a dilution testing schema using a 2:1 ampicillin-sulbactam ratio or a fixed concentration of c4 1xg of sulbactam per ml. A 2:1 ratio test is also used for the orally administered amoxicillin-clavulanate combination (9) . Ampicillin-sulbactam in vitro tests have previously used a 1:1 ratio of the components as disks or in dilution test systems (4; Jones, in press). Results of studies presented here and elsewhere indicate very little difference between these test ratios, but some species-specific differences have been identified (7, 15, 16, 20 ; Jones, in press). We suggest the use of the 2:1 ratio for dilution test 
